Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630322 | 1.00 | BACE1 (0.41) | BACE1CTSDPTPN1OPRD1OPRM1 | |
| SCHEMBL29590592 | 0.96 | BACE1 (0.39) | BACE1CTSDPTPN1OPRD1 | |
| SCHEMBL31314295 | 0.94 | BACE1 (0.44) | BACE1CTSDPTPN1OPRD1OPRM1 | |
| SCHEMBL29630382 | 0.94 | BACE1 (0.36) | BACE1CTSD | |
| SCHEMBL31474495 | 0.94 | BACE1 (0.33) | BACE1OPRD1 | |
| SCHEMBL29630654 | 0.91 | OPRD1 (0.37) | BACE1OPRD1OPRM1OPRK1 | |
| SCHEMBL29383357 | 0.91 | ECE1 (0.34) | — | |
| SCHEMBL29589213 | 0.91 | FNTA (0.42) | — | |
| SCHEMBL30607941 | 0.90 | BACE1 (0.41) | BACE1CTSDPTPN1 | |
| SCHEMBL29511114 | 0.90 | BACE1 (0.41) | BACE1CTSDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | BACE1 530/4885CTSD 3399/4885PTPN1 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.